Search Within

Weining Ma

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Body Imaging Service (6)
  2. Department of Medicine (6)
  3. GSK Faculty (6)
  4. Human Oncology and Pathogenesis Program (6)
  5. Radiology, Department of (6)
  6. Solid Tumor Oncology Division (6)

More Groups

People
  1. Clifford Hudis (5)
  2. David Solit (5)
  3. Shanu Modi (5)
  4. Neal Rosen (4)
  5. Larry Norton (3)
  6. Steven Sugarman (3)

More People

Years
  1. 2024 (1)
  2. 2011 (1)
  3. 2008 (1)
  4. 2007 (2)
  5. 2006 (1)
Publications
  1. Annals of Oncology (1)
  2. Breast Cancer Research and Treatment (1)
  3. Cancer Research (1)
  4. Clinical Cancer Research (1)
  5. International Journal of Gynecological Cancer (1)
  6. Journal of Clinical Oncology (1)
Publishers
  1. American Association for Cancer Research (2)
  2. American Society of Clinical Oncology (1)
  3. Lippincott Williams & Wilkins (1)
  4. Oxford University Press (1)
  5. Springer (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Monitoring response to immune checkpoint inhibition in patients with endometrial cancer using cell-free DNA analysis
    Meeting Abstract

    Manning-Geist, B.; Patel, J.; Marra, A.; Zammarrelli, W. A. 3rd; Da Cruz Paula, A.; Abu-Rustum, N.; Shah, R.; Berger, M.; Hensley, M.; Lakhman, Y.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
    Meeting Abstract

    Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
    Journal Article

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)
    Meeting Abstract

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Solit, D.; Bagatell, R.; Ma, W.; Wheler, J.; Cropp, G. F.; Rosen, N.; Johnson, R. G. Jr; more...
    Cancer Research (2006)

    Fulltext@MSK | Save